Exosome Diagnostics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.exosomedx.com
ExoDx Prostate Evaluation in Active Surveillance Patient Population
- Conditions
- Prostate Cancer
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05572099
- Locations
- 🇺🇸
Chesapeake Urology, Towson, Maryland, United States
Urine Biomarker for Kidney Transplant Rejection
- Conditions
- Graft Rejection
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05072951
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
- Conditions
- Urologic Cancer
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04720599
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Baltimore, Maryland, United States
🇺🇸New Jersey Urology, Voorhees, New Jersey, United States
🇩🇪Klinikum der Universität München, München, Germany
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
- Conditions
- Prostate Cancer
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04357717
- Locations
- 🇺🇸
New Jersey Urology, Voorhees, New Jersey, United States
🇺🇸Chesapeake Urology Research Associates, Baltimore, Maryland, United States
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03236675
- Locations
- 🇺🇸
Ochsner Medical Center, New Orleans, Louisiana, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
- Conditions
- Metastatic Castrate Resistant Prostate Cancer
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03236688
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Decision Impact Trial of the ExoDx Prostate (IntelliScore)
- Conditions
- Cancer of the Prostate
- Interventions
- Diagnostic Test: ExoDx Prostate (IntelliScore)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT03235687
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
- Conditions
- Cancer of Prostate
- Interventions
- Diagnostic Test: ExoDx Prostate Intelliscore
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT03031418
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Southeastern Urology Associates, Macon, Georgia, United States
🇺🇸Premier Urology Group, Edison, New Jersey, United States
Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Other: ExoIntelliScore Prostate
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Exosome Diagnostics, Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT02702856